Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-19 01:35 | 2025-12-16 | RCUS | Arcus Biosciences, Inc. | ROSEN TERRY J | Director, Officer | SELL | $22.01 | 54,691 | $1,203,957 | 2,194,809 |
| 2025-12-19 01:03 | 2025-12-18 | IMNM | Immunome Inc. | SIEGALL CLAY B | Director, Officer | BUY | $21.50 | 46,511 | $999,987 | 853,247 |
| 2025-12-18 18:34 | 2025-12-16 | GALT | GALECTIN THERAPEUTICS INC | 10X Fund, L.P. | 10% owner | SELL | $6.66 | 30,681 | $204,335 | 5,614,457 |
| 2025-12-18 00:05 | 2025-12-15 | VERA | Vera Therapeutics, Inc. | Turner William D. | Officer | OPT+S | $50.08 | 10,000 | $500,767 | 22,500 |
| 2025-12-18 01:43 | 2025-12-16 | RPRX | Royalty Pharma plc | Urist Marshall | Officer | SELL | $38.32 | 20,000 | $766,420 | 140,000 |
| 2025-12-18 01:39 | 2025-12-15 | RPRX | Royalty Pharma plc | Coyne Terrance P. | Officer | SELL | $38.36 | 69,582 | $2,669,172 | 43,510 |
| 2025-12-18 01:53 | 2025-12-15 | ARQT | Arcutis Biotherapeutics Inc. | Burnett Patrick | Officer | OPT+S | $28.94 | 11,500 | $332,851 | 98,307 |
| 2025-12-18 00:37 | 2025-12-15 | KNSA | Kiniksa Pharmaceuticals International, plc | Tessari Eben | Officer | OPT+S | $41.56 | 12,048 | $500,715 | 16,666 |
| 2025-12-18 00:23 | 2025-12-15 | LFVN | Lifevantage Corp | Lewis Darwin | Director | BUY | $6.54 | 805 | $5,265 | 131,553 |
| 2025-12-18 03:19 | 2025-12-16 | ORIC | Oric Pharmaceuticals, Inc. | Piscitelli Dominic | Officer | OPT+S | $9.06 | 10,720 | $97,127 | 68,148 |
| 2025-12-18 00:10 | 2025-12-15 | FULC | Fulcrum Therapeutics, Inc. | Oltmans Curtis Gale | Officer | SELL | $12.92 | 3,452 | $44,600 | 10,252 |
| 2025-12-18 05:00 | 2025-12-15 | ROIV | Roivant Sciences Ltd. | Gline Matthew | Director, Officer | OPT+S | $21.68 | 1,740,000 | $37,723,200 | 18,616,406 |
| 2025-12-18 01:25 | 2025-12-12 | HRMY | Harmony Biosciences Holdings, Inc. | Dayno Jeffrey M. | Director, Officer | OPT+S | $40.11 | 25,933 | $1,040,103 | 0 |
| 2025-12-18 03:18 | 2025-12-16 | ORIC | Oric Pharmaceuticals, Inc. | Chacko Jacob | Director, Officer | OPT+S | $9.06 | 33,374 | $302,368 | 581,711 |
| 2025-12-18 03:21 | 2025-12-16 | ORIC | Oric Pharmaceuticals, Inc. | Multani Pratik S | Officer | OPT+S | $9.06 | 10,720 | $97,129 | 68,149 |
| 2025-12-17 15:00 | 2025-12-16 | RNXT | RenovoRx, Inc. | Agah Ramtin | Director, Officer | BUY | $0.85 | 12,000 | $10,200 | 778,460 |
| 2025-12-18 00:14 | 2025-12-16 | RZLT | Rezolute, Inc. | Hogenhuis Wladimir | Director | BUY | $1.69 | 5,650 | $9,549 | 119,675 |
| 2025-12-18 00:13 | 2025-12-16 | RZLT | Rezolute, Inc. | ROBERTS BRIAN KENNETH | Officer | BUY | $1.70 | 28,000 | $47,600 | 308,352 |
| 2025-12-18 00:38 | 2025-12-15 | KNSA | Kiniksa Pharmaceuticals International, plc | Quart Barry D | Director | OPT+S | $41.51 | 20,129 | $835,555 | 12,546 |
| 2025-12-18 03:56 | 2025-12-16 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Officer | OPT+S | $2.96 | 3,227 | $9,562 | 0 |
| 2025-12-18 02:21 | 2025-12-15 | FOLD | AMICUS THERAPEUTICS, INC. | Campbell Bradley L | Director, Officer | OPT+S | $10.86 | 77,926 | $846,011 | 1,129,782 |
| 2025-12-18 02:19 | 2025-12-15 | FOLD | AMICUS THERAPEUTICS, INC. | Clark David Michael | Officer | SELL | $11.00 | 25,643 | $282,073 | 271,332 |
| 2025-12-18 02:28 | 2025-12-15 | HOWL | Werewolf Therapeutics, Inc. | EVNIN LUKE | Director | SELL | $1.08 | 48,171 | $51,952 | 2,841,957 |
| 2025-12-18 00:47 | 2025-12-15 | ONC | BeOne Medicines Ltd. | OYLER JOHN | Director, Officer | SELL | $306.59 | 100,000 | $30,659,420 | 0 |
| 2025-12-17 00:52 | 2025-12-15 | BCAX | Bicara Therapeutics Inc. | Cohlhepp Ryan | Director, Officer | OPT+S | $18.68 | 12,500 | $233,548 | 189,141 |
| 2025-12-17 01:07 | 2025-12-15 | RAPP | Rapport Therapeutics, Inc. | Bredt David | Officer | SELL | $30.02 | 8,500 | $255,130 | 392,642 |
| 2025-12-17 01:41 | 2025-12-15 | SXTP | 60 DEGREES PHARMACEUTICALS, INC. | DOW GEOFFREY S | Director, Officer | BUY | $0.80 | 9,670 | $7,759 | 59,618 |
| 2025-12-17 02:36 | 2025-12-12 | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | Officer | SELL | $188.31 | 1,804 | $339,711 | 26,186 |
| 2025-12-17 00:30 | 2025-12-12 | TYRA | Tyra Biosciences, Inc. | Bensen Daniel | Officer | SELL | $22.64 | 8,000 | $181,159 | 162,981 |
| 2025-12-17 05:31 | 2025-12-15 | IRON | Disc Medicine, Inc. | Savage William Jacob | Officer | SELL | $91.22 | 13,093 | $1,194,372 | 75,702 |
| 2025-12-17 02:27 | 2025-12-15 | BBIO | BridgeBio Pharma, Inc. | Kumar Neil | Director, Officer | OPT+S | $74.64 | 30,011 | $2,239,901 | 228,776 |
| 2025-12-17 04:15 | 2025-12-12 | MNKD | MANNKIND CORP | Castagna Michael | Director, Officer | OPT+S | $6.00 | 42,116 | $252,696 | 2,504,792 |
| 2025-12-17 00:05 | 2025-12-12 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% owner | BUY | $40.00 | 87 | $3,480 | 371,795 |
| 2025-12-17 05:43 | 2025-12-12 | IRON | Disc Medicine, Inc. | Bitterman Kevin | Director | OPT+S | $91.56 | 184,123 | $16,858,633 | 14,161 |
| 2025-12-16 17:30 | 2025-12-15 | RLMD | RELMADA THERAPEUTICS, INC. | TRAVERSA SERGIO | Director, Officer | BUY | $4.12 | 27,500 | $113,300 | 1,300,000 |
| 2025-12-16 17:30 | 2025-12-15 | RLMD | RELMADA THERAPEUTICS, INC. | Shenouda Maged | Officer | BUY | $4.12 | 11,665 | $48,060 | 800,000 |
| 2025-12-17 02:34 | 2025-12-15 | SILO | Silo Pharma, Inc. | Weisblum Eric | Director, Officer | BUY | $0.42 | 5,000 | $2,075 | 216,932 |
| 2025-12-17 00:23 | 2025-12-15 | TVTX | Travere Therapeutics, Inc. | Calvin Sandra | Officer | SELL | $36.00 | 2,910 | $104,760 | 45,635 |
| 2025-12-16 21:14 | 2025-12-15 | ARWR | Arrowhead Pharmaceuticals Inc. | Anzalone Christopher Richard | Director, Officer | SELL | $67.00 | 184,298 | $12,348,795 | 3,916,957 |
| 2025-12-16 22:59 | 2025-12-12 | NATR | NATURES SUNSHINE PRODUCTS INC | Yates Bryant J | Officer | SELL | $22.29 | 1,700 | $37,893 | 98,604 |
| 2025-12-17 01:00 | 2025-12-12 | CPRX | CATALYST PHARMACEUTICALS, INC. | Harper Molly | Director | OPT+S | $23.25 | 26,746 | $621,919 | 2,360 |
| 2025-12-17 00:42 | 2025-12-12 | ELAN | Elanco Animal Health Inc | Kurzius Lawrence Erik | Director | BUY | $21.30 | 10,000 | $213,000 | 131,773 |
| 2025-12-17 02:59 | 2025-12-12 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Officer | OPT+S | $3.26 | 1,700 | $5,541 | 0 |
| 2025-12-17 00:16 | 2025-12-12 | PGEN | PRECIGEN, INC. | KINDLER JEFFREY B | Director | SELL | $3.63 | 235,467 | $855,899 | 110,603 |
| 2025-12-17 02:00 | 2025-12-12 | CLRB | Cellectar Biosciences, Inc. | NEIS JOHN | Director | SELL | $3.70 | 198 | $732 | 10 |
| 2025-12-17 00:22 | 2025-12-12 | GALT | GALECTIN THERAPEUTICS INC | Shlevin Harold H. | Director | OPT+S | $6.28 | 28,210 | $177,210 | 11,206 |
| 2025-12-17 00:33 | 2025-12-15 | UTHR | UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL | Officer | OPT+S | $496.30 | 22,500 | $11,166,723 | 0 |
| 2025-12-17 01:09 | 2025-12-15 | UTHR | UNITED THERAPEUTICS Corp | EDGEMOND JAMES | Officer | OPT+S | $495.36 | 3,517 | $1,742,193 | 8,142 |
| 2025-12-17 00:30 | 2025-12-15 | UTHR | UNITED THERAPEUTICS Corp | PATUSKY CHRISTOPHER | Director | OPT+S | $495.95 | 1,000 | $495,954 | 1,490 |
| 2025-12-17 01:08 | 2025-12-15 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $494.09 | 8,000 | $3,952,689 | 130 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.